Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)

Anthony V. Serritella; Amy Taylor; Michael C. Haffner; Wassim Abida; Alan Bryce; Lawrence I. Karsh; Scott T. Tagawa; Przemyslaw Twardowski; Andrew J. Armstrong; Joshua M. Lang

doi:10.1038/s41391-024-00887-z

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)

Anthony V. Serritella
, Amy Taylor
, Michael C. Haffner
, Wassim Abida
, Alan Bryce
, Lawrence I. Karsh
, Scott T. Tagawa
, Przemyslaw Twardowski
, Andrew J. Armstrong
, Joshua M. Lang

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Background/Objectives: Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. Subjects/Methods: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. Results/Conclusions: In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.

Original language	English
Pages (from-to)	601-609
Number of pages	9
Journal	Prostate Cancer and Prostatic Diseases
Volume	28
Issue number	3
DOIs	https://doi.org/10.1038/s41391-024-00887-z
State	Published - Sep 2025
Externally published	Yes

Access to Document

10.1038/s41391-024-00887-z

Cite this

@article{b8c37a664b87430c97ccfa6ba4ab22c8,

title = "Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)",

abstract = "Background/Objectives: Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. Subjects/Methods: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. Results/Conclusions: In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.",

author = "Serritella, \{Anthony V.\} and Amy Taylor and Haffner, \{Michael C.\} and Wassim Abida and Alan Bryce and Karsh, \{Lawrence I.\} and Tagawa, \{Scott T.\} and Przemyslaw Twardowski and Armstrong, \{Andrew J.\} and Lang, \{Joshua M.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2025",

month = sep,

doi = "10.1038/s41391-024-00887-z",

language = "English",

volume = "28",

pages = "601--609",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)

AU - Serritella, Anthony V.

AU - Taylor, Amy

AU - Haffner, Michael C.

AU - Abida, Wassim

AU - Bryce, Alan

AU - Karsh, Lawrence I.

AU - Tagawa, Scott T.

AU - Twardowski, Przemyslaw

AU - Armstrong, Andrew J.

AU - Lang, Joshua M.

PY - 2025/9

Y1 - 2025/9

N2 - Background/Objectives: Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. Subjects/Methods: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. Results/Conclusions: In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.

AB - Background/Objectives: Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. Subjects/Methods: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. Results/Conclusions: In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.

UR - https://www.scopus.com/pages/publications/85205065796

U2 - 10.1038/s41391-024-00887-z

DO - 10.1038/s41391-024-00887-z

M3 - Review article

C2 - 39333696

AN - SCOPUS:85205065796

SN - 1365-7852

VL - 28

SP - 601

EP - 609

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 3

ER -

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this